Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.

Bolognani F, Del Valle Rubido M, Squassante L, Wandel C, Derks M, Murtagh L, Sevigny J, Khwaja O, Umbricht D, Fontoura P.

Sci Transl Med. 2019 May 8;11(491). pii: eaat7838. doi: 10.1126/scitranslmed.aat7838. Epub 2019 May 1.

PMID:
31043521
2.

Adaptive behavior in adolescents and adults with Down syndrome: Results from a 6-month longitudinal study.

Spiridigliozzi GA, Goeldner C, Edgin J, Hart SJ, Noeldeke J, Squassante L, Visootsak J, Heller JH, Khwaja O, Kishnani PS, Liogier d'Ardhuy X.

Am J Med Genet A. 2019 Jan;179(1):85-93. doi: 10.1002/ajmg.a.60685. Epub 2018 Dec 20.

PMID:
30569586
3.

Health-Related Quality of Life in Individuals with Down Syndrome: Results from a Non-Interventional Longitudinal Multi-National Study.

Rofail D, Froggatt D, de la Torre R, Edgin J, Kishnani P, Touraine R, Whitwham S, Squassante L, Khwaja O, D'Ardhuy XL.

Adv Ther. 2017 Aug;34(8):2058-2069. doi: 10.1007/s12325-017-0591-y. Epub 2017 Aug 9.

PMID:
28795347
4.

A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder.

Umbricht D, Del Valle Rubido M, Hollander E, McCracken JT, Shic F, Scahill L, Noeldeke J, Boak L, Khwaja O, Squassante L, Grundschober C, Kletzl H, Fontoura P.

Neuropsychopharmacology. 2017 Aug;42(9):1924. doi: 10.1038/npp.2017.92.

5.

A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder.

Umbricht D, Del Valle Rubido M, Hollander E, McCracken JT, Shic F, Scahill L, Noeldeke J, Boak L, Khwaja O, Squassante L, Grundschober C, Kletzl H, Fontoura P.

Neuropsychopharmacology. 2017 Aug;42(9):1914-1923. doi: 10.1038/npp.2016.232. Epub 2016 Oct 6. Erratum in: Neuropsychopharmacology. 2017 Aug;42(9):1924.

6.

Assessment of Cognitive Scales to Examine Memory, Executive Function and Language in Individuals with Down Syndrome: Implications of a 6-month Observational Study.

Liogier d'Ardhuy X, Edgin JO, Bouis C, de Sola S, Goeldner C, Kishnani P, Nöldeke J, Rice S, Sacco S, Squassante L, Spiridigliozzi G, Visootsak J, Heller J, Khwaja O.

Front Behav Neurosci. 2015 Nov 18;9:300. doi: 10.3389/fnbeh.2015.00300. eCollection 2015.

7.

Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia.

Ratti E, Carpenter DJ, Zamuner S, Fernandes S, Squassante L, Danker-Hopfe H, Archer G, Robertson J, Alexander R, Trist DG, Merlo-Pich E.

Sleep. 2013 Dec 1;36(12):1823-30. doi: 10.5665/sleep.3208.

8.

The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia.

Bettica P, Squassante L, Zamuner S, Nucci G, Danker-Hopfe H, Ratti E.

Sleep. 2012 Aug 1;35(8):1097-104. doi: 10.5665/sleep.1996.

9.

Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia.

Bettica P, Squassante L, Groeger JA, Gennery B, Winsky-Sommerer R, Dijk DJ.

Neuropsychopharmacology. 2012 Apr;37(5):1224-33. doi: 10.1038/npp.2011.310. Epub 2012 Jan 11.

10.

Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder.

Ratti E, Bellew K, Bettica P, Bryson H, Zamuner S, Archer G, Squassante L, Bye A, Trist D, Krishnan KR, Fernandes S.

J Clin Psychopharmacol. 2011 Dec;31(6):727-33. doi: 10.1097/JCP.0b013e31823608ca. Erratum in: J Clin Psychopharmacol. 2012 Apr;32(2):185.

PMID:
22020354
11.

Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist.

Bettica P, Nucci G, Pyke C, Squassante L, Zamuner S, Ratti E, Gomeni R, Alexander R.

J Psychopharmacol. 2012 Aug;26(8):1058-70. doi: 10.1177/0269881111408954. Epub 2011 Jul 5.

PMID:
21730017
12.

Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study.

Stone JM, Erlandsson K, Arstad E, Squassante L, Teneggi V, Bressan RA, Krystal JH, Ell PJ, Pilowsky LS.

Psychopharmacology (Berl). 2008 Apr;197(3):401-8. doi: 10.1007/s00213-007-1047-x. Epub 2008 Jan 5.

PMID:
18176855
13.

Sample size calculation for the Power Model for dose proportionality studies.

Sethuraman VS, Leonov S, Squassante L, Mitchell TR, Hale MD.

Pharm Stat. 2007 Jan-Mar;6(1):35-41.

PMID:
17323313
14.

Simple graphical methods of displaying multiple clinical results.

Squassante L, Robinson CN, Palmer RL.

Pharm Stat. 2006 Jan-Mar;5(1):51-60.

PMID:
17080928
15.

Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: Part 1--pseudoequilibrium interval and quantification methods.

Catafau AM, Danus M, Bullich S, Llop J, Perich J, Cunningham VJ, Plaza P, Penengo MM, Eersels JL, Squassante L, Ros D, Barbanoj M.

J Nucl Med. 2006 Jun;47(6):919-28.

16.

Ketamine displaces the novel NMDA receptor SPET probe [(123)I]CNS-1261 in humans in vivo.

Stone JM, Erlandsson K, Arstad E, Bressan RA, Squassante L, Teneggi V, Ell PJ, Pilowsky LS.

Nucl Med Biol. 2006 Feb;33(2):239-43.

PMID:
16546678
17.

Characterization of a 7% carbon dioxide (CO2) inhalation paradigm to evoke anxiety symptoms in healthy subjects.

Poma SZ, Milleri S, Squassante L, Nucci G, Bani M, Perini GI, Merlo-Pich E.

J Psychopharmacol. 2005 Sep;19(5):494-503.

PMID:
16166187
18.

Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h.

Teneggi V, Tiffany ST, Squassante L, Milleri S, Ziviani L, Bye A.

Psychopharmacology (Berl). 2005 Nov;183(1):1-12. Epub 2005 Oct 22.

PMID:
16160876
19.

EEG power spectra and auditory P300 during free smoking and enforced smoking abstinence.

Teneggi V, Squassante L, Milleri S, Polo A, Lanteri P, Ziviani L, Bye A.

Pharmacol Biochem Behav. 2004 Jan;77(1):103-9.

PMID:
14724047
20.

Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers.

Da Ros L, Squassante L, Milleri S.

Clin Pharmacokinet. 2003;42(1):99-106.

PMID:
12489980
21.

Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal.

Teneggi V, Tiffany ST, Squassante L, Milleri S, Ziviani L, Bye A.

Psychopharmacology (Berl). 2002 Nov;164(2):177-87. Epub 2002 Aug 27.

PMID:
12404080
22.

Correlation and predictive performances of saliva and plasma nicotine concentration on tobacco withdrawal-induced craving.

Teneggi V, Squassante L, Iavarone L, Milleri S, Bye A, Gomeni R.

Br J Clin Pharmacol. 2002 Oct;54(4):407-14.

23.

Absolute quantification of cerebral blood flow with magnetic resonance, reproducibility of the method, and comparison with H2(15)O positron emission tomography.

Carroll TJ, Teneggi V, Jobin M, Squassante L, Treyer V, Hany TF, Burger C, Wang L, Bye A, Von Schulthess GK, Buck A.

J Cereb Blood Flow Metab. 2002 Sep;22(9):1149-56.

PMID:
12218421
24.
25.

Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions.

Kirby S, Falcoz C, Daniel MJ, Milleri S, Squassante L, Ziviani L, Ventresca GP.

Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):781-91.

PMID:
11294367
26.

The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects.

Ziviani L, Da Ros L, Squassante L, Milleri S, Cugola M, Iavarone LE.

Br J Clin Pharmacol. 2001 Feb;51(2):147-52.

27.

From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs.

Kunka R, Andrews S, Pimazzoni M, Callejas S, Ziviani L, Squassante L, Daley-Yates PT.

Respir Med. 2000 Jun;94 Suppl B:S10-6.

28.

Troglitazone has no effect on red cell mass or other erythropoietic parameters.

Young MM, Squassante L, Wemer J, van Marle SP, Dogterom P, Jonkman JH.

Eur J Clin Pharmacol. 1999 Apr;55(2):101-4.

PMID:
10335903
29.

Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. SLMT02 Italian Study Group.

Di Lorenzo G, Morici G, Drago A, Pellitteri ME, Mansueto P, Melluso M, Norrito F, Squassante L, Fasolo A.

Clin Ther. 1998 Nov-Dec;20(6):1130-48.

PMID:
9916607
30.

Fine needles with echo markers: increasing cell dragging during biopsy.

Buscarini E, Foroni R, Rossi S, Di Stasi M, Silva M, Marinone G, Degli Antoni G, Buscarini L, Squassante L.

Acta Cytol. 1997 Jul-Aug;41(4):1246-9. No abstract available.

PMID:
9250333
31.

Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer.

Rossi S, Di Stasi M, Buscarini E, Quaretti P, Garbagnati F, Squassante L, Paties CT, Silverman DE, Buscarini L.

AJR Am J Roentgenol. 1996 Sep;167(3):759-68.

PMID:
8751696
32.

Clinical presentation, diagnostic work-up and therapeutic choices in two consecutive series of patients with hepatocellular carcinoma.

Buscarini L, Di Stasi M, Buscarini E, Fornari F, Squassante L, Rossi S, Silva M.

Oncology. 1996 May-Jun;53(3):204-9.

PMID:
8643222
33.

Evaluation of personality as a component of the healthy condition of volunteers participating in phase I studies.

Berto D, Milleri S, Squassante L, Baroldi PA.

Eur J Clin Pharmacol. 1996;51(3-4):209-13.

PMID:
9010686
34.

Incidence of gallstones in a population of patients with cirrhosis.

Fornari F, Imberti D, Squillante MM, Squassante L, Civardi G, Buscarini E, Cavanna L, Caturelli E, Buscarini L.

J Hepatol. 1994 Jun;20(6):797-801.

PMID:
7930481
35.

A study of plasma disposition kinetics of lacidipine after single oral ascending doses.

Squassante L, Caveggion E, Braggio S, Pellegatti M, Baroldi P.

J Cardiovasc Pharmacol. 1994;23 Suppl 5:S94-7.

PMID:
7609516
36.

Hepatocellular carcinoma in liver cirrhosis. A prospective study.

Imberti D, Fornari F, Sbolli G, Buscarini E, Squassante L, Buscarini L.

Scand J Gastroenterol. 1993 Jun;28(6):540-4.

PMID:
7686686
37.

Effects of therapeutic doses of salbutamol alone and combined with beclomethasone dipropionate on airway responsiveness and cyclic AMP plasma levels in asthmatic patients.

Ferrari M, Testi R, Romito D, Adami S, Olivieri M, Squassante L, Prior M, Lo Cascio V.

Respiration. 1993;60(2):78-83.

PMID:
8393581
38.

Effects of antihypertensive therapy with lacidipine on ambulatory blood pressure in the elderly.

Zito M, Abate G, Cervone C, Squassante L, Calabrese G.

J Hypertens Suppl. 1991 Dec;9(3):S79-83.

PMID:
1798006
39.

Different dosage regimens of ranitidine in the short-term therapy of duodenal ulcer: a multicentre trial.

Castelli G, Squassante L, Uleri S, Zanferrari G.

Int J Clin Pharmacol Res. 1991;11(1):41-9.

PMID:
1874580

Supplemental Content

Loading ...
Support Center